



Stargardt's Disease Diagnosed in Adults: Case Report

Thiago Sande Miguel ^a, Felipe Bekman Diniz Mitleg Rocha ^a,
Tais Cristina Rossett ^b, Daniel Almeida da Costa ^{c*}
and Maurício Bastos Pereira ^a

^a Universidade Federal Fluminense, Brazil.

^b Centro Universitário Fundação Assis Gurgacz, Brazil.

^c UNIFAA, Centro Universitario de Valença, Brazil.

Authors' contributions

This work was carried out in collaboration among all authors. Authors TSM, FBDMR, TCR, MBP and DADC designed the study, conceptualized the data and definition of intellectual content, clinical studies, experimental studies, data acquisition and literature searches. Authors FBDMR, TCR, MBP and DADC performed the manuscript preparation, manuscript editing and manuscript review. All authors read and approved the final manuscript.

Article Information

DOI: 10.9734/OR/2021/v15i430219

Open Peer Review History:

This journal follows the Advanced Open Peer Review policy. Identity of the Reviewers, Editor(s) and additional Reviewers, peer review comments, different versions of the manuscript, comments of the editors, etc are available here: <https://www.sdiarticle5.com/review-history/80248>

Case Study

Received 21 October 2021
Accepted 23 December 2021
Published 24 December 2021

ABSTRACT

Aims: To describe a Stargardt disease, (STGD1) is an autosomal recessive inherited disease often associated with mutations in ABCA4 and characterized by the accumulation of autofluorescent lipofuscin deposits in the retinal pigment epithelium (RPE).

Presentation of Case: J.A.D.L, male, 52 years old, foreman, born in Rio de Janeiro, attends the ophthalmologic consultation complaining of progressive low visual acuity, noticed at around 31 years of age.

Discussion: Stargardt disease is the most common hereditary macular dystrophy, representing 7% of retinal dystrophies. The first and only clinical manifestation is the decrease in central vision, which predominantly starts between six and fifteen years of age.

Methodology: Case report.

Results: Therefore, the referral of young patients with visual complaints without initial abnormalities of the fundus of the eye for ophthalmological evaluation is essential, since the diagnosis of patients at an early stage of the disease is increasingly important with the advent of new therapeutic possibilities.

Conclusion: Although many factors contribute to the phenotype of patients with STGD1, the expression and residual activity of ABCA4 mutants play an important role in determining disease severity.

Retinal thickness and disease duration influence the visual prognosis of patients. Patients with Stargardt's disease have a smaller macular thickness when compared to normal individuals, and this reduction is related to the duration of the pathology. Therefore, OCT is fundamental for the follow-up of these patients, contributing to a better prognostic assessment of the disease.

Keywords: Autosomal recessive inheritance; stargardt's disease; retinal dystrophy; pisciform deposits; lipofuscin accumulation.

1. INTRODUCTION

Stargardt disease (STGD1) is the most common recessive macular dystrophy and is characterized by decreased central vision, atrophy of the macula and the underlying retinal pigment epithelium, and is associated with disease-causing sequence variants in the ABCA4 gene [1-4].

It is usually inherited in an autosomal recessive way by mutations in the ABCA4 gene, located on chromosome 1, region p13-p21, whose protein product is involved in ATP-dependent membrane transport of both cones and rods, however there is great genetic heterogeneity [2-5].

Genetically, STGD is a heterogeneous disorder usually inherited as an autosomal recessive disorder, but rarely presents as an autosomal dominant trait with a later onset of clinical symptoms. A recessive locus has been mapped to chromosome 1p (STGD type 1) [1-3]. This gene encodes a retina-specific transmembrane protein, ABCA4, which belongs to the family of membrane transporters of the ATP Binding Cassette (ABC) type [2,3].

The retinal pigment epithelium (RPE) and the macular region's photoreceptor layer are the most compromised sites. The classic fundus aspect of the disease is of beaten bronze macular lesions and yellowish-white pisciform lesions known as "flecks", corresponding to the accumulation of lipofuscin in the apical pole of the RPE cells [2,4,6,7].

The clinical features of the disease vary according to the severity of its genotype and the sensitivity of the foveal cones and retinal pigment epithelium (RPE) to this genotype. Low visual acuity is the most common clinical manifestation, ranging from 20/30 to 20/200, while the age of

onset can range from 5 to 50 years of age [2,4,6,7].

The dispersed pisciform deposits ("flecks") in the posterior pole may extend to the middle periphery, and macular alterations may be found in 50% of patients. Decreased visual acuity often precedes fundus changes and depends on the age of onset of symptoms, so that the later the onset, the less likely there is to be visual loss. In the late stage of the disease, far visual acuity stabilizes at approximately 20/200 [4,6,7,8].

The diagnosis of Stargardt's disease is based on clinical history and fundus changes, and complementary tests are essential in this context. Fluorescein angiography (FFA) is a widely used diagnostic method and can confirm the diagnosis of Stargardt, as hyperfluorescent pisciform lesions, varying degrees of macular atrophy, which can present an aspect of target maculopathy and choroidal silence, are more evident. It is a hypofluorescence by choriocapillary blockage, due to the accumulation of lipofuscin in the RPE, present in around 80% of the cases, which practically seals the diagnosis, although the absence does not exclude this disease [5,8,9,10,11]. Standard electroretinogram (ERG) and electrooculogram do not represent valuable diagnostic tools, as functional loss is initially restricted to retinal focal areas. Multifocal ERG has been shown to be useful in detecting foveal dysfunction in Stargardt's disease, even at early stages, being important in the diagnosis and helping to describe the topography of loss of cone activity more precisely [2,12,13,14].

Optical coherence tomography (OCT) provides high resolution images of the retinal layers and is used to detect macular changes in retinal dystrophies. Multifocal ERG and OCT have the ability to quantify intraretinal changes in early stages of the disease, which aids in the patient's prognosis [9,15-18].

2. CASE REPORT

J.A.D.L, male, 52 years old, foreman, born in Rio de Janeiro, attends the ophthalmologic consultation complaining of progressive low visual acuity, noticed at around 31 years of age. The picture initially manifested itself as difficulty reading traffic signs. Reports an episode of sudden visual loss lasting about 5 seconds for 8 years with spontaneous improvement.

The patient reported that, over the years, there was a worsening of visual acuity in both eyes, which was indolent and progressive, even having sought medical help, but without success. Claims good peripheral vision and a lot of difficulty focusing on objects, as central vision is blurry.

In the past pathological history, he claims to have systemic arterial hypertension. Denies diabetes, eye trauma, previous eye surgeries and any eye pathologies. Denies previous ophthalmic procedures, daily use of eye drops and family members with glaucoma.

Visual acuity (VA) with the best correction for central vision was finger count (CD) at 2.0 meters in the OD and CD at 1.0 meter in the OE. Peripheral vision was 20/150 in both eyes.

Biomicroscopy was within normal limits.

Intraocular pressure: 11/11mmHg at 12:00

Funduscopy showed regular optic discs, excavation/physiological disc ratio in AO, vascular arcades without alterations, posterior pole with bilateral white-yellow lesions of various sizes and shapes, such as round, oval or in a pisciform shape that did not extend to the middle periphery retinal, areas of atrophy of the pigmented epithelium, without choroidal neovascularization. Retinas applied, no areas of detachment. (Figs. 1 and 2)

The visual field examination had the reliability indices within normal parameters, showing areas of central scotoma in the AO and the RE with already loss of peripheral vision. (Figs. 3 and 4)

Fluorescein angiography showed areas of diffuse hypofluorescence compatible with "choroid silence" and "bull's eye" hyperfluorescence in the macular region, being compatible with Stargardt's Disease in both eyes. (Figs. 5 and 6)

The patient is under regular follow-up at the retinal outpatient clinic, with visual acuity maintained since the last consultation under conservative treatment. Therefore, the referral of young patients with visual complaints without initial abnormalities of the fundus of the eye for ophthalmological evaluation is essential, since the diagnosis of patients at an early stage of the disease is increasingly important with the advent of new therapeutic possibilities.




Fig. 1. Right eye retinogram



Fig. 2. Left eye retinogram




Fig. 3. Visual field 24.2 of the right eye




Fig. 4. Visual field 24.2 of the left eye




Fig. 5. Fluorescein angiography of the right eye




Fig. 6. Fluorescein angiography of the left eye

3. DISCUSSION

Stargardt disease is the most common hereditary macular dystrophy, representing 7% of retinal dystrophies. The first and only clinical manifestation is the decrease in central vision, which predominantly starts between six and fifteen years of age [17,19-22]. In exceptional cases, as in our report, symptoms start in the third decade of life.

Findings in the fundus of the eye depend on the form of presentation and clinical course of the disease, and may, in some cases, affect older patients. In advanced stages, visual acuity varies between 20/200 to finger count [18,21,23-25]. The current visual acuity of the patient presented is similar to that found in the literature in advanced cases of the pathology, which shows that early diagnosis, good amnesia and detailed examination are essential for early diagnosis.

Among the differential diagnoses considered, macular diseases are included, such as: X-linked retinoschisis; vitelliform macular dystrophy; progressive cone dystrophy; familial druse; and fundus albipunctatus [14,22,24-27]. All these pathologies were excluded in the patient in the present report.

Retinal degeneration observed in Stargardt's disease is believed to be caused by the accumulation of lipofuscin in the RPE, resulting in death of RPE cells and photoreceptors, leading to atrophic lesions seen in the macula in the late stage of the disease. Described [12,24-28].

The characteristics of STGD1 vary widely due to the marked phenotypic heterogeneity associated with the large number of disease-causing sequence variants identified in ABCA4. There are several manifestations of the disease, resulting in a spectrum of clinical presentations, progression rates, imaging tests, psychophysical and electrophysiological findings, and variable prognosis [15,19,22,26-29].

STGD1 commonly presents as progressive bilateral central vision loss, most often onset in childhood and a second peak incidence in early adulthood. 15-17,22,26 There is growing evidence that onset is related to the severity of underlying ABCA4 variants with childhood-onset STGD1 being associated with more deleterious variants compared with adult-onset or late-onset [18,26,28-30].

Initially, ophthalmoscopy may reveal a normal fundus or mild retinal abnormalities, including

loss of the foveal reflex or mild RPE disturbance, with or without loss of vision. Diagnosis can therefore be delayed unless retinal images with background autofluorescence, OCT and an electrophysiological assessment are performed, just as happened with our patient, being diagnosed late and documented with imaging exams already in advanced stages of the disease. Illness [14-19,30,31].

OCT provides a quantitative assessment of the retinal layers, with a good correlation between the images obtained and the corresponding anatomical structure, allowing for a better assessment of macular alterations. OCT provides high-resolution images, proving to be of great help in the assessment of macular diseases, since it is possible to objectively and accurately quantify retinal thickness, thus aiding in diagnosis and follow-up [22,28-31].

OCT can show the loss of normal retinal architecture starting in the central macula with relative preservation of the peripheral macula in the early stages of the disease. Importantly, up to a third of children at initial presentation may not show “flecks” on funduscopy or autofluorescence [13,18,20,22]. These pisciform deposits develop over time and are associated with increased macular atrophy. another reason why the diagnosis is usually delayed, which probably happened to our patient [2,26,29,30].

4. CONCLUSION

Stargardt's disease is an autosomal recessive retinal dystrophy, characterized by a dysfunction of the cones in the central region before the appearance of pisciform deposits, RPE atrophy or abnormalities in complementary exams such as OCT, fluorescein angiography, autofluorescence and full-field electroretinography. The progressive loss of bilateral central vision that can later progress to impairment of peripheral vision is characteristic.

Although many factors contribute to the phenotype of patients with STGD1, the expression and residual activity of ABCA4 mutants play an important role in determining disease severity.

Retinal thickness and disease duration influence the visual prognosis of patients. Patients with Stargardt's disease have a smaller macular thickness when compared to normal individuals, and this reduction is related to the duration of the

pathology. Therefore, OCT is fundamental for the follow-up of these patients, contributing to a better prognostic assessment of the disease.

Unfortunately, due to the high cost of the OCT exam, the patient cannot afford the cost of carrying out this exam, since this exam was unavailable to perform in the service free of charge.

Therefore, the referral of young patients with visual complaints without initial abnormalities of the fundus of the eye for ophthalmological evaluation is essential, since the diagnosis of patients at an early stage of the disease is increasingly important with the advent of new therapeutic possibilities.

CONSENT

All authors declare that ‘written informed consent was obtained from the patient (or other approved parties) for publication of this case report and accompanying images’.

ETHICAL APPROVAL

It is not applicable.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Sisk RA, Leng T. Multimodal imaging and multifocal electroretinography demonstrate autosomal recessive Stargardt disease may present like occult macular dystrophy. *Retina*. 2014 Aug;34(8):1567-75.
2. Heath Jeffery RC, Chen FK. Stargardt disease: Multimodal imaging: A review. *Clin Exp Ophthalmol*. 2021 Jul;49(5):498-515.
3. Ritter M, Zotter S, Schmidt WM, Bittner RE, Deak GG, Pircher M, Sacu S, Hitzenberger CK, Schmidt-Erfurth UM; Macula Study Group Vienna. Characterization of stargardt disease using polarization-sensitive optical coherence tomography and fundus autofluorescence imaging. *Invest Ophthalmol Vis Sci*. 2013 Sep 27;54(9):6416-25.
4. Iida T. [Pathophysiology of macular diseases--morphology and function].

- Nippon Ganka Gakkai Zasshi. 2011 Mar;115(3):238-74; discussion 275. Japanese.
5. El Matri L, Falfoul Y, Kortli M, Hassairi A, Charfi H, Turki A, Kort F, Chebil A. Intérêt de l'imagerie multimodale dans les différents stades de la maladie de Stargardt [Contribution of multimodal imaging in the various stages of Stargardt disease]. *J Fr Ophtalmol*. 2017 Oct;40(8):666-675. French.
 6. Georgiou M, Fujinami K, Michaelides M. Retinal imaging in inherited retinal diseases. *Ann Eye Sci*. 2020 Sep;5:25. doi: 10.21037/aes-20-81. Epub 2020 Sep 15.
 7. Hohman TC. Hereditary Retinal Dystrophy. *Handb Exp Pharmacol*. 2017;242:337-367.
 8. 8-Bax NM, Lambertus S, Cremers FPM, Klevering BJ, Hoyng CB. The absence of fundus abnormalities in Stargardt disease. *Graefes Arch Clin Exp Ophthalmol*. 2019 Jun;257(6):1147-1157.
 9. Glöckle N, Kohl S, Mohr J, Scheurenbrand T, Sprecher A, Weisschuh N, Bernd A, Rudolph G, Schubach M, Poloschek C, Zrenner E, Biskup S, Berger W, Wissinger B, Neidhardt J. Panel-based next generation sequencing as a reliable and efficient technique to detect mutations in unselected patients with retinal dystrophies. *Eur J Hum Genet*. 2014 Jan;22(1):99-104.
 10. Weisschuh N, Mayer AK, Strom TM, Kohl S, Glöckle N, Schubach M, Andreasson S, Bernd A, Birch DG, Hamel CP, Heckenlively JR, Jacobson SG, Kamme C, Kellner U, Kunstmann E, Maffei P, Reiff CM, Rohrschneider K, Rosenberg T, Rudolph G, Vámos R, Varsányi B, Weleber RG, Wissinger B. Mutation Detection in Patients with Retinal Dystrophies Using Targeted Next Generation Sequencing. *PLoS One*. 2016 Jan 14;11(1):e0145951.
 11. Bravo-Gil N, Méndez-Vidal C, Romero-Pérez L, González-del Pozo M, Rodríguez-de la Rúa E, Dopazo J, Borrego S, Antiñolo G. Improving the management of Inherited Retinal Dystrophies by targeted sequencing of a population-specific gene panel. *Sci Rep*. 2016 Apr 1;6:23910.
 12. Melillo P, Testa F, Rossi S, Di Iorio V, Orrico A, Auricchio A, Simonelli F. En Face Spectral-Domain Optical Coherence Tomography for the Monitoring of Lesion Area Progression in Stargardt Disease. *Invest Ophthalmol Vis Sci*. 2016;57(9):OCT247-52.
 13. Liu X, Xiao J, Huang H, Guan L, Zhao K, Xu Q, Zhang X, Pan X, Gu S, Chen Y, Zhang J, Shen Y, Jiang H, Gao X, Kang X, Sheng X, Chen X, Zhao C. Molecular genetic testing in clinical diagnostic assessments that demonstrate correlations in patients with autosomal recessive inherited retinal dystrophy. *JAMA Ophthalmol*. 2015 Apr;133(4):427-36.
 14. Cai CX, Light JG, Handa JT. Quantifying the Rate of Ellipsoid Zone Loss in Stargardt Disease. *Am J Ophthalmol*. 2018 Feb;186:1-9.
 15. Bolz HJ. Herausforderungen und Fallstricken zum Trotz: Wie die Ophthalmologie von Next-Generation Sequencing profitiert [Despite Challenges and Pitfalls: How Ophthalmology Benefits from the Use of Next-Generation Sequencing]. *Klin Monbl Augenheilkd*. 2018 Mar;235(3):258-263.
 16. Bolz HJ. Genetische Diagnostik von Netzhautdystrophien : Revolutionierung durch neue Methoden der DNA-Sequenzierung [Genetic diagnostics of retinal dystrophies : Breakthrough with new methods of DNA sequencing]. *Ophthalmologe*. 2018;115(12):1028-1034. German.
 17. Georgiou M, Fujinami K, Michaelides M. Inherited retinal diseases: Therapeutics, clinical trials and end points-A review. *Clin Exp Ophthalmol*. 2021 Apr;49(3):270-288.
 18. Giani A, Pellegrini M, Carini E, Peroglio Deiro A, Bottoni F, Staurenghi G. The dark atrophy with indocyanine green angiography in Stargardt disease. *Invest Ophthalmol Vis Sci*. 2012 Jun 26;53(7):3999-4004.
 19. Nunes RP, Rosa PR, Giani A, Goldhardt R, Thomas B, Garcia Filho CA, Gregori G, Feuer W, Lam BL, Staurenghi G, Rosenfeld PJ. Choroidal Thickness in Eyes With Central Geographic Atrophy Secondary to Stargardt Disease and Age-Related Macular Degeneration. *Ophthalmic Surg Lasers Imaging Retina*. 2015 Sep;46(8):814-22.
 20. Cicinelli MV, Battista M, Starace V, Battaglia Parodi M, Bandello F. Monitoring and Management of the Patient with Stargardt Disease. *Clin Optom (Auckl)*. 2019 Nov 28;11:151-165.
 21. Tsang SH, Sharma T. Stargardt Disease. *Adv Exp Med Biol*. 2018;1085:139-151.

22. Haji Abdollahi S, Hirose T. Stargardt-Fundus flavimaculatus: recent advancements and treatment. *Semin Ophthalmol.* 2013 Sep-Nov;28(5-6):372-6.
23. Fishman GA. Historical evolution in the understanding of Stargardt macular dystrophy. *Ophthalmic Genet.* 2010;31(4):183-9.
24. Molday RS. Insights into the Molecular Properties of ABCA4 and Its Role in the Visual Cycle and Stargardt Disease. *Prog Mol Biol Transl Sci.* 2015;134:415-31.
25. Georgiou M, Kane T, Tanna P, Bouzia Z, Singh N, Kalitzeos A, Strauss RW, Fujinami K, Michaelides M. Prospective Cohort Study of Childhood-Onset Stargardt Disease: Fundus Autofluorescence Imaging, Progression, Comparison with Adult-Onset Disease, and Disease Symmetry. *Am J Ophthalmol.* 2020 Mar;211:159-175.
26. Corton M, Nishiguchi KM, Avila-Fernández A, Nikopoulos K, Riveiro-Alvarez R, Tatu SD, Ayuso C, Rivolta C. Exome sequencing of index patients with retinal dystrophies as a tool for molecular diagnosis. *PLoS One.* 2013;8(6):e65574.
27. Huang XF, Huang F, Wu KC, Wu J, Chen J, Pang CP, Lu F, Qu J, Jin ZB. Genotype-phenotype correlation and mutation spectrum in a large cohort of patients with inherited retinal dystrophy revealed by next-generation sequencing. *Genet Med.* 2015 Apr;17(4):271-8.
28. Bolz HJ. Next-Generation Sequencing: Quantensprung für Forschung und Diagnostik in der Ophthalmologie [Next-Generation Sequencing: A Quantum Leap in Ophthalmology Research and Diagnostics]. *Klin Monbl Augenheilkd.* 2017 Mar;234(3):280-288.
29. Banda HK, Shah GK, Blinder KJ. Applications of fundus autofluorescence and widefield angiography in clinical practice. *Can J Ophthalmol.* 2019 Feb;54(1):11-19.
30. Pichi F, Abboud EB, Ghazi NG, Khan AO. Fundus autofluorescence imaging in hereditary retinal diseases. *Acta Ophthalmol.* 2018 Aug;96(5):e549-e561.
31. Heath Jeffery RC, Chen FK. Stargardt disease: Multimodal imaging: A review. *Clin Exp Ophthalmol.* 2021;49(5):498-515.

© 2021 Miguel et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:

The peer review history for this paper can be accessed here:
<https://www.sdiarticle5.com/review-history/80248>